Cantor Fitzgerald initiated coverage of InflaRx (IFRX) with an Overweight rating and $10 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- InflaRx Approves Key Resolutions at Annual Shareholder Meeting
- InflaRx N.V. Announces 2025 Annual General Meeting Agenda
- InflaRx’s Promising Drug Pipeline and Market Potential Drive Buy Rating
- InflaRx price target raised to $10 from $7 at Guggenheim
- Promising Prospects for InflaRx’s Gohibic: Buy Rating Supported by Positive Phase 3 Developments and Market Potential